Oncotarget

Reviews:

The IgH 3’ regulatory region and c-myc-induced B-cell lymphomagenesis

Nour Ghazzaui, Alexis Saintamand, Hussein Issaoui, Christelle Vincent-Fabert and Yves Denizot _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:7059-7067. https://doi.org/10.18632/oncotarget.12535

Metrics: PDF 1366 views  |   HTML 1789 views  |   ?  


Abstract

Nour Ghazzaui1,*, Alexis Saintamand1,*, Hussein Issaoui1, Christelle Vincent-Fabert1 and Yves Denizot1

1 Université de Limoges, Centre National de la Recherche Scientifique, CNRS UMR, France

* These authors have have contributed equally to this work

Correspondence to:

Yves Denizot, email:

Keywords: c-myc, 3’ regulatory region, lymphomagenesis, transgenic mice, HDAC

Received: August 15, 2016 Accepted: October 05, 2016 Published: October 08, 2016

Abstract

Deregulation and mutations of c-myc have been reported in multiple mature B-cell malignancies such as Burkitt lymphoma, myeloma and plasma cell lymphoma. After translocation into the immunoglobulin heavy chain (IgH) locus, c-myc is constitutively expressed under the control of active IgH cis-regulatory enhancers. Those located in the IgH 3’ regulatory region (3’RR) are master control elements of transcription. Over the past decade numerous convincing demonstrations of 3’RR’s contribution to mature c-myc-induced lymphomagenesis have been made using transgenic models with various types of IgH-c-myc translocations and transgenes. This review highlights how IgH 3’RR physiological functions play a critical role in c-myc deregulation during lymphomagenesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12535